CAJ | 학술논문

以BCA为单体材料,采用乳液聚合法制备IVM-PBCA-NP纳米粒,经药物吸附和PVP包被后形成PVP-IVM-PBCA-NP载药纳米粒。经正交试验设计确定以BCA：IVM投量为4：1（g/g）,BCA投量为0.4：25（V/V）,乳化剂F68浓度为2%,搅拌速度600r/min,反应体系pH值为2、3、6,反应时间3h,为最佳制备条件。在该条件下所制备的PVP-IVM-PBCA-NP药物包封率为（45.43±1.65）%,载药量（9.95±0.23）%,主要粒径为296nm。
이BCA위단체재료,채용유액취합법제비IVM-PBCA-NP납미립,경약물흡부화PVP포피후형성PVP-IVM-PBCA-NP재약납미립。경정교시험설계학정이BCA：IVM투량위4：1（g/g）,BCA투량위0.4：25（V/V）,유화제F68농도위2%,교반속도600r/min,반응체계pH치위2、3、6,반응시간3h,위최가제비조건。재해조건하소제비적PVP-IVM-PBCA-NP약물포봉솔위（45.43±1.65）%,재약량（9.95±0.23）%,주요립경위296nm。
Taking BCA as monomer material,ivermectin polybutylcyanoacrylate nanoparticles（IVM-PBCA-NP） were prepared by emulsion polymerization method.The drug-loaded PVP-IVM-PBCA-NP was formed after drug adsorption and PVP coating.The optimum preparation conditions were confirmed by the orthogonal test as follows：the dosage ratio of BCA to IVM was 4：1（g/g）,the dosage of BCA was 0.4：25（V/V）,the concentration of emulsifier F68 was 2%,stirring speed was 600 r/min,reaction system pH was 2,3 and 6,reaction time was 3 h.Under these conditions,the drug encapsulation ratio of the prepared PVP-IVM-PBCA-NP was（45.43±1.65）%,the drug-loading capacity was（9.95±0.23）% and the main particle size was 296 nm.